已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Three-Year Clinical Trial of Low-Concentration Atropine for Myopia Progression (LAMP) Study: Continued Versus Washout

医学 屈光度 阿托品 眼科 冲刷 随机化 麻醉 随机对照试验 内科学 视力
作者
Jason C. S. Yam,Xiu Juan Zhang,Yuzhou Zhang,Yumeng Wang,Shu Min Tang,Fen Fen Li,Ka Wai Kam,Simon T. C. Ko,Benjamin Hon Kei Yip,Alvin Lerrmann Young,Clement Chee Yung Tham,Li Jia Chen,Chi Pui Pang
出处
期刊:Ophthalmology [Elsevier BV]
卷期号:129 (3): 308-321 被引量:222
标识
DOI:10.1016/j.ophtha.2021.10.002
摘要

Purpose (1) To compare the efficacy of continued and stopping treatment for 0.05%, 0.025%, and 0.01% atropine during the third year. (2) To evaluate the efficacy of continued treatment over 3 years. (3) To investigate the rebound phenomenon and its determinants after cessation of treatment. Design A randomized, double-masked extended trial. Participants A total of 350 of 438 children aged 4 to 12 years originally recruited into the Low-Concentration Atropine for Myopia Progression (LAMP) study. Methods At the beginning of the third year, children in each group were randomized at a 1:1 ratio to continued treatment and washout subgroups. Cycloplegic spherical equivalent (SE) refraction and axial length (AL) were measured at 4-month intervals. Main Outcome Measures Changes in SE and AL between groups. Results A total of 326 children completed 3 years of follow-up. During the third year, SE progression and AL elongation were faster in the washout subgroups than in the continued treatment groups across all concentrations: –0.68 ± 0.49 diopters (D) versus –0.28 ± 0.42 D (P < 0.001) and 0.33 ± 0.17 mm versus 0.17 ± 0.14 mm (P < 0.001) for the 0.05%; –0.57 ± 0.38 D versus –0.35 ± 0.37 D (P = 0.004) and 0.29 ± 0.14 mm versus 0.20 ± 0.15 mm (P = 0.001) for the 0.025%; –0.56 ± 0.40 D versus –0.38 ± 0.49 D (P = 0.04) and 0.29 ± 0.15 mm versus 0.24 ± 0.18 mm (P = 0.13) for the 0.01%. Over the 3-year period, SE progressions were –0.73 ± 1.04 D, –1.31 ± 0.92 D, and –1.60 ± 1.32 D (P = 0.001) for the 0.05%, 0.025%, and 0.01% groups in the continued treatment subgroups, respectively, and −1.15 ± 1.13 D, –1.47 ± 0.77 D, and –1.81 ± 1.10 D (P = 0.03), respectively, in the washout subgroup. The respective AL elongations were 0.50 ± 0.40 mm, 0.74 ± 0.41 mm, and 0.89 ± 0.53 mm (P < 0.001) for the continued treatment subgroups and 0.70 ± 0.47 mm, 0.82 ± 0.37 mm, and 0.98 ± 0.48 mm (P = 0.04) for the washout subgroup. The rebound SE progressions during washout were concentration dependent, but their differences were clinically small (P = 0.15). Older age and lower concentration were associated with smaller rebound effects in both SE progression (P < 0.001) and AL elongation (P < 0.001). Conclusions During the third year, continued atropine treatment achieved a better effect across all concentrations compared with the washout regimen. 0.05% atropine remained the optimal concentration over 3 years in Chinese children. The differences in rebound effects were clinically small across all 3 studied atropine concentrations. Stopping treatment at an older age and lower concentration are associated with a smaller rebound. (1) To compare the efficacy of continued and stopping treatment for 0.05%, 0.025%, and 0.01% atropine during the third year. (2) To evaluate the efficacy of continued treatment over 3 years. (3) To investigate the rebound phenomenon and its determinants after cessation of treatment. A randomized, double-masked extended trial. A total of 350 of 438 children aged 4 to 12 years originally recruited into the Low-Concentration Atropine for Myopia Progression (LAMP) study. At the beginning of the third year, children in each group were randomized at a 1:1 ratio to continued treatment and washout subgroups. Cycloplegic spherical equivalent (SE) refraction and axial length (AL) were measured at 4-month intervals. Changes in SE and AL between groups. A total of 326 children completed 3 years of follow-up. During the third year, SE progression and AL elongation were faster in the washout subgroups than in the continued treatment groups across all concentrations: –0.68 ± 0.49 diopters (D) versus –0.28 ± 0.42 D (P < 0.001) and 0.33 ± 0.17 mm versus 0.17 ± 0.14 mm (P < 0.001) for the 0.05%; –0.57 ± 0.38 D versus –0.35 ± 0.37 D (P = 0.004) and 0.29 ± 0.14 mm versus 0.20 ± 0.15 mm (P = 0.001) for the 0.025%; –0.56 ± 0.40 D versus –0.38 ± 0.49 D (P = 0.04) and 0.29 ± 0.15 mm versus 0.24 ± 0.18 mm (P = 0.13) for the 0.01%. Over the 3-year period, SE progressions were –0.73 ± 1.04 D, –1.31 ± 0.92 D, and –1.60 ± 1.32 D (P = 0.001) for the 0.05%, 0.025%, and 0.01% groups in the continued treatment subgroups, respectively, and −1.15 ± 1.13 D, –1.47 ± 0.77 D, and –1.81 ± 1.10 D (P = 0.03), respectively, in the washout subgroup. The respective AL elongations were 0.50 ± 0.40 mm, 0.74 ± 0.41 mm, and 0.89 ± 0.53 mm (P < 0.001) for the continued treatment subgroups and 0.70 ± 0.47 mm, 0.82 ± 0.37 mm, and 0.98 ± 0.48 mm (P = 0.04) for the washout subgroup. The rebound SE progressions during washout were concentration dependent, but their differences were clinically small (P = 0.15). Older age and lower concentration were associated with smaller rebound effects in both SE progression (P < 0.001) and AL elongation (P < 0.001). During the third year, continued atropine treatment achieved a better effect across all concentrations compared with the washout regimen. 0.05% atropine remained the optimal concentration over 3 years in Chinese children. The differences in rebound effects were clinically small across all 3 studied atropine concentrations. Stopping treatment at an older age and lower concentration are associated with a smaller rebound.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI6.2的应助被认真的莹采纳,获得10
3秒前
小小瓜发布了新的文献求助10
3秒前
3秒前
4秒前
调皮访烟完成签到,获得积分20
4秒前
十九完成签到,获得积分10
4秒前
6秒前
调皮访烟发布了新的文献求助10
7秒前
7秒前
银杏发布了新的文献求助10
10秒前
Cynthia完成签到 ,获得积分10
10秒前
VDC的应助被科研通管家采纳,获得30
11秒前
11秒前
11秒前
天天快乐的应助被科研通管家采纳,获得10
11秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
11秒前
12秒前
12秒前
今后的应助被rebecca采纳,获得10
12秒前
Cakoibao的应助被科研通管家采纳,获得10
12秒前
海伦发布了新的文献求助10
12秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
12秒前
科研通AI2S的应助被王百万采纳,获得10
16秒前
冰冰完成签到 ,获得积分10
16秒前
周周发布了新的文献求助10
16秒前
宋忠赫完成签到,获得积分10
16秒前
Thaumatin完成签到,获得积分20
16秒前
科研通AI6.4的应助被HL采纳,获得10
17秒前
zhouzhou发布了新的文献求助10
17秒前
小小瓜完成签到,获得积分10
18秒前
天天向上的应助被DawnQinghui采纳,获得10
19秒前
23秒前
23秒前
23秒前
26秒前
Akim的应助被奔跑的猫猫采纳,获得10
26秒前
ket的应助被奔跑的猫猫采纳,获得10
26秒前
26秒前
呆萌威完成签到,获得积分10
27秒前
28秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194612
求助须知:如何正确求助?哪些是违规求助? 9580394
关于积分的说明 21870930
捐赠科研通 7794182
什么是DOI,文献DOI怎么找? 3437711
关于科研通互助平台的介绍 2561001
邀请新用户注册赠送积分活动 2484411